Brief: Sensei Biotherapeutics Reports Encouraging Clinical Data From Dose Escalation Portion Of Its Phase 1/2 Trial Of SNS-101

Faeth Therapeutics,

23/05/2024 23:57

May 23 (Reuters) - Sensei Biotherapeutics Inc  SNSE.O :
    * SENSEI BIOTHERAPEUTICS INC: REPORTED ENCOURAGING CLINICAL
DATA
FROM DOSE ESCALATION PORTION OF ITS PHASE 1/2 TRIAL OF SNS-101
    * SENSEI BIOTHERAPEUTICS INC: ONCE EVERY 3-WEEK DOSING OF
SNS-101
DEMONSTRATES INITIAL SIGNS OF PROMISING CLINICAL ACTIVITY
    * SENSEI BIOTHERAPEUTICS INC: PHARMACOKINETIC AND SAFETY
PROFILE
VALIDATE CONDITIONALLY ACTIVE APPROACH IN STUDY
    * SENSEI BIOTHERAPEUTICS INC: EXPECTS TO REPORT INITIAL DATA
FROM
DOSE EXPANSION COHORTS AND TO HOLD AN END-OF-PHASE 1 MEETING
WITH FDA BY END OF 2024

Source text for Eikon:  ID:nGNX8TCQQv 
Further company coverage:  SNSE.O 

 ((Reuters.Briefs@thomsonreuters.com;))